NCT00658762 - A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 for the Treatment of Generalized Anxiety Disorder (3) | Biotech Hunter

Enrollment

286

Participants

Timeline

Start Date

May 31, 2008

Primary Completion Date

April 30, 2009

Study Completion Date

April 30, 2009

Conditions

Generalized Anxiety Disorder

Interventions

DRUG

PD 0332334

Capsules, oral, 225 mg BID, 8 weeks, with 2 week taper

DRUG

PD 0332334

Capsules, oral, 300 mg BID, 8 weeks, with 2 week taper

DRUG

paroxetine

Capsules, oral, 20 mg q am, 8 weeks, with 2 week taper

DRUG

Placebo

Capsules, oral, BID, 8 weeks, with 2 week taper

Trial Locations (28)

1135

Pfizer Investigational Site, Budapest

13210

Pfizer Investigational Site, Syracuse

19063

Pfizer Investigational Site, Media

19401

Pfizer Investigational Site, Norristown

30060

Pfizer Investigational Site, Marietta

30328

Pfizer Investigational Site, Atlanta

32763

Pfizer Investigational Site, Orange City

33912

Pfizer Investigational Site, Fort Myers

35226

Pfizer Investigational Site, Birmingham

44122

Pfizer Investigational Site, Beachwood

45227

Pfizer Investigational Site, Cincinnati

46143

Pfizer Investigational Site, Greenwood

67207

Pfizer Investigational Site, Wichita

68131

Pfizer Investigational Site, Omaha

73103

Pfizer Investigational Site, Oklahoma City

73116

Pfizer Investigational Site, Oklahoma City

75231

Pfizer Investigational Site, Dallas

77008

Pfizer Investigational Site, Houston

77074

Pfizer Investigational Site, Houston

91206

Pfizer Investigational Site, Glendale

91786

Pfizer Investigational Site, Upland

92591

Pfizer Investigational Site, Temecula

92595

Pfizer Investigational Site, Wildomar

92868

Pfizer Investigational Site, Orange

97301

Pfizer Investigational Site, Salem

10021-4256

Pfizer Investigational Site, New York

44109-1998

Pfizer Investigational Site, Cleveland

05091

Pfizer Investigational Site, Woodstock